{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:19:53Z","timestamp":1794575993778,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,5,26]]},"DOI":"10.1038\/s41416-020-0802-1","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T19:03:38Z","timestamp":1585767818000},"page":"1630-1637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":989,"title":["Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours"],"prefix":"10.1038","volume":"122","author":[{"given":"David S.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasgit","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ejadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-7162","authenticated-orcid":false,"given":"Jae-Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangjoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Stoudemire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kelnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Bonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas G.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Beg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"key":"802_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell\n116, 281\u2013297 (2004).","journal-title":"Cell"},{"key":"802_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell\n136, 215\u2013233 (2009).","journal-title":"Cell"},{"key":"802_CR3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer\n6, 857\u2013866 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"802_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","volume":"6","author":"A Esquela-Kerscher","year":"2006","unstructured":"Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer\n6, 259\u2013269 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"802_CR5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nrc3166","volume":"11","author":"AL Kasinski","year":"2011","unstructured":"Kasinski, A. L. & Slack, F. J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer\n11, 849\u2013864 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"802_CR6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","volume":"6","author":"MD Jansson","year":"2012","unstructured":"Jansson, M. D. & Lund, A. H. MicroRNA and Cancer. Mol. Oncol.\n6, 590\u2013610 (2012).","journal-title":"Mol. Oncol."},{"key":"802_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","volume":"3","author":"AG Bader","year":"2012","unstructured":"Bader, A. G. miR-34\u2013a microRNA replacement therapy is headed to the clinic. Front Genet\n3, 120 (2012).","journal-title":"Front Genet"},{"key":"802_CR8","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1038\/mtna.2015.47","volume":"4","author":"MA Cortez","year":"2015","unstructured":"Cortez, M. A., Valdecanas, D., Niknam, S. et al. In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Mol. Ther.\u2014Nucleic Acids\n4, e270 (2015).","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"802_CR9","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"AG Bader","year":"2010","unstructured":"Bader, A. G., Brown, D. & Winkler, M. The promise of microRNA replacement therapy. Cancer Res\n70, 7027\u20137030 (2010).","journal-title":"Cancer Res"},{"key":"802_CR10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","volume":"19","author":"P Trang","year":"2011","unstructured":"Trang, P., Wiggins, J. F., Daige, D. L. et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther.\n19, 1116\u20131122 (2011).","journal-title":"Mol. Ther."},{"key":"802_CR11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/gt.2011.79","volume":"18","author":"AG Bader","year":"2011","unstructured":"Bader, A. G., Brown, D., Stoudemire, J. et al. Developing therapeutic microRNAs for cancer. Gene Ther.\n18, 1121\u20131126 (2011).","journal-title":"Gene Ther."},{"key":"802_CR12","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","volume":"13","author":"CL Daige","year":"2014","unstructured":"Daige, C. L., Wiggins, J. F., Priddy, L. et al. Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol. Cancer Ther.\n13, 2352\u20132360 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"802_CR13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1021\/ac403044t","volume":"86","author":"K Kelnar","year":"2014","unstructured":"Kelnar, K., Peltier, H. J., Leatherbury, N. et al. Quantification of therapeutic miRNA mimics in whole blood from non-human primates. Anal. Chem.\n86, 1534\u20131542 (2014).","journal-title":"Anal. Chem."},{"key":"802_CR14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","volume":"35","author":"MS Beg","year":"2017","unstructured":"Beg, M. S., Brenner, A. J., Sachdev, J. et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest N. Drugs\n35, 180\u2013188 (2017).","journal-title":"Invest N. Drugs"},{"key":"802_CR15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","volume":"447","author":"L He","year":"2007","unstructured":"He, L., He, X., Lim, L. P. et al. A microRNA component of the p53 tumor suppressor network. Nature\n447, 1130\u20131134 (2007).","journal-title":"Nature"},{"key":"802_CR16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","volume":"17","author":"H Hermeking","year":"2010","unstructured":"Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ.\n17, 193\u2013199 (2010).","journal-title":"Cell Death Differ."},{"key":"802_CR17","first-page":"678","volume":"21","author":"J Zhao","year":"2013","unstructured":"Zhao, J., Lammers, P., Torrance, C. J. et al. TP53-independent function of miR-34a via HDAC1 and p21(CIP1\/WAF1). Mol. Ther.\n21, 678\u2013686 (2013).","journal-title":"Mol. Ther."},{"key":"802_CR18","first-page":"2709","volume":"8","author":"J Wang","year":"2015","unstructured":"Wang, J., Dan, G., Zhao, J. et al. The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther.\n8, 2709\u20132719 (2015).","journal-title":"Onco Targets Ther."},{"key":"802_CR19","doi-asserted-by":"crossref","first-page":"e77983","DOI":"10.1371\/journal.pone.0077983","volume":"8","author":"J Shin","year":"2013","unstructured":"Shin, J., Danli, X. & Zhong, X. P. MicroRNA-34a enhances T cell activation by targeting diacylglycerol Kinase \u03b6. PLoS ONE\n8, e77983 (2013).","journal-title":"PLoS ONE"},{"key":"802_CR20","doi-asserted-by":"crossref","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","volume":"108","author":"MA Cortez","year":"2016","unstructured":"Cortez, M. A., Ivan, C., Valdecanas, D. et al. PDL1 regulation by p53 via miR-34. J. Natl Cancer Inst.\n108, djv303 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"802_CR21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","volume":"27","author":"X Wang","year":"2015","unstructured":"Wang, X., Li, J., Dong, K. et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal\n27, 443\u2013452 (2015).","journal-title":"Cell Signal"},{"key":"802_CR22","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","volume":"4","author":"Q Ji","year":"2009","unstructured":"Ji, Q., Hao, X., Zhang, M. et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE\n4, e6816 (2009).","journal-title":"PLoS ONE"},{"key":"802_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canlet.2008.09.035","volume":"275","author":"N Li","year":"2009","unstructured":"Li, N., Fu, H., Tie, Y. et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett.\n275, 44\u201353 (2009).","journal-title":"Cancer Lett."},{"key":"802_CR24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","volume":"17","author":"C Liu","year":"2011","unstructured":"Liu, C., Kelnar, K., Liu, B. et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med.\n17, 211\u2013215 (2011).","journal-title":"Nat. Med."},{"key":"802_CR25","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","volume":"18","author":"MT Di Martino","year":"2012","unstructured":"Di Martino, M. T., Leone, E., Amodio, N. et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin. Cancer Res.\n18, 6260\u20136270 (2012).","journal-title":"Clin. Cancer Res."},{"key":"802_CR26","doi-asserted-by":"crossref","unstructured":"Zhao, J., Kelnar, K. & Bader, A. G. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS ONE.\n9, e89105 (2014).","DOI":"10.1371\/journal.pone.0089105"},{"key":"802_CR27","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-10-0655","volume":"70","author":"JF Wiggins","year":"2010","unstructured":"Wiggins, J. F., Ruffino, L., Kelnar, K. et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res.\n70, 5923\u20135930 (2010).","journal-title":"Cancer Res."},{"key":"802_CR28","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1038\/leu.2012.110","volume":"26","author":"VJ Craig","year":"2012","unstructured":"Craig, V. J., Tzankov, A., Flori, M. et al. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia\n26, 2421\u20132424 (2012).","journal-title":"Leukemia"},{"key":"802_CR29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","volume":"73","author":"AW Tolcher","year":"2014","unstructured":"Tolcher, A. W., Rodrigueza, W. V., Rasco, D. W. et al. A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother. Pharm.\n73, 363\u2013371 (2014).","journal-title":"Cancer Chemother. Pharm."},{"key":"802_CR30","doi-asserted-by":"crossref","unstructured":"Kelnar, K. & Bader A. B. A qRT-PCR method for determining the biodistribution profile of a miR-34a mimic. in Gene Therapy of Solid Cancers: Methods and Protocols, Methods in Molecular Biology (eds Walther, W. & Stein, U.) Ch 8, Vol. 1317, 125\u2013133, Humana Press, New York City (2015).","DOI":"10.1007\/978-1-4939-2727-2_8"},{"key":"802_CR31","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/bioinformatics\/btq545","volume":"26","author":"N Bartonicek","year":"2010","unstructured":"Bartonicek, N. & Enright, A. J. SylArray: a web server for automated detection of miRNA effects from expression data. Bioinformatics\n26, 2900\u20132901 (2010).","journal-title":"Bioinformatics"},{"key":"802_CR32","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nmeth.1267","volume":"5","author":"S van Dongen","year":"2008","unstructured":"van Dongen, S., Abreu-Goodger, C. & Enright, A. J. Detecting microRNA binding and siRNA off-target effects from expression data. Nat. Methods\n5, 1023\u20131025 (2008).","journal-title":"Nat. Methods"},{"key":"802_CR33","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cub.2007.06.068","volume":"17","author":"GT Bommer","year":"2007","unstructured":"Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E. et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol.\n17, 1298\u20131307 (2007).","journal-title":"Curr. Biol."},{"key":"802_CR34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1541-7786.MCR-07-2102","volume":"6","author":"KA Cole","year":"2008","unstructured":"Cole, K. A., Attiyeh, E. F., Mosse, Y. P., Laquaglia, M. J., Diskin, S. J., Brodeur, G. M. et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res\n6, 735\u2013742 (2008).","journal-title":"Mol. Cancer Res"},{"key":"802_CR35","volume":"8","author":"Q Ji","year":"2008","unstructured":"Ji, Q., Hao, X., Meng, Y., Zhang, M., Desano, J., Fan, D. et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer\n8, 266 (2008).","journal-title":"BMC Cancer"},{"key":"802_CR36","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.2337\/db07-1252","volume":"57","author":"P Lovis","year":"2008","unstructured":"Lovis, P., Roggli, E., Laybutt, D. R., Gattesco, S., Yang, J. Y., Widmann, C. et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes\n57, 2728\u20132736 (2008).","journal-title":"Diabetes"},{"key":"802_CR37","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","volume":"13","author":"CL Daige","year":"2014","unstructured":"Daige, C. L., Wiggins, J. F., Priddy, L., Nelligan-Davis, T., Zhao, J. & Brown, D. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol. Cancer Ther.\n13, 2352\u20132360 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"802_CR38","first-page":"ra71","volume":"4","author":"NH Kim","year":"2011","unstructured":"Kim, N. H., Kim, H. S., Kim, N. G., Lee, I., Choi, H. S., Li, X. Y. et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal\n4, ra71 (2011).","journal-title":"Sci. Signal"},{"key":"802_CR39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.immuni.2010.06.013","volume":"33","author":"DS Rao","year":"2010","unstructured":"Rao, D. S., O\u2019Connell, R. M., Chaudhuri, A. A., Garcia-Flores, Y., Geiger, T. L. & Baltimore, D. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity\n33, 48\u201359 (2010).","journal-title":"Immunity"},{"key":"802_CR40","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1182\/blood-2010-10-312231","volume":"117","author":"VJ Craig","year":"2011","unstructured":"Craig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H. et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood\n117, 6227\u20136236 (2011).","journal-title":"Blood"},{"key":"802_CR41","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/mt.2013.148","volume":"21","author":"J Zhao","year":"2013","unstructured":"Zhao, J., Lammers, P., Torrance, C. J. & Bader, A. G. TP53-independent function of miR-34a via HDAC1 and p21CIP1\/WAF1. Mol. Ther.\n21, 1678\u20131686 (2013).","journal-title":"Mol. Ther."},{"key":"802_CR42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1089\/hum.2008.131","volume":"19","author":"M Robbins","year":"2008","unstructured":"Robbins, M., Judge, A., Ambegia, E. et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther.\n19, 991\u2013999 (2008).","journal-title":"Hum. Gene Ther."},{"key":"802_CR43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/jir.2014.0034","volume":"34","author":"S Chattopadhyay","year":"2014","unstructured":"Chattopadhyay, S. & Sen, G. C. dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J. Interf. Cytokine Res\n34, 427\u2013436 (2014).","journal-title":"J. Interf. Cytokine Res"},{"key":"802_CR44","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli, K. B., Strissel, P. L., Desrichard, A. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell\n162, 974\u2013986 (2015).","journal-title":"Cell"},{"key":"802_CR45","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D., Hoos, A., O\u2019Day, S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res.\n15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"802_CR46","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol.\n33, 1974\u20131982 (2015).","journal-title":"J. Clin. Oncol."},{"key":"802_CR47","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C., Schachter, J., Long, G. V. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med\n372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med"},{"key":"802_CR48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J., Tannir, N. M., McDermott, D. F. et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med.\n378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"802_CR49","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B., Sangro, B., Yau, T. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet\n389, 2492\u20132502 (2017).","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0802-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0802-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T08:02:35Z","timestamp":1703923355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0802-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0802-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"31 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study followed the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. Patients were enrolled with approval from ethics committees and institutional review boards at participating institutions (UT Health Science Center, San Antonio, TX; UT Southwestern Medical Center, Dallas, TX; Scottsdale Healthcare Research Institute, Scottsdale, AZ; Mayo Clinic Cancer Center, Scottsdale, AZ; UT MD Anderson Cancer Center, Houston, TX; Asan Medical Center, Seoul, Korea; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Severance Hospital, Seoul Korea, USO Dallas TX; SCRI Boulder, CO), and all patients provided written informed consent before starting study-specific procedures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available due proprietary restrictions but are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"D.S.H. Research\/Grant Funding: AbbVie, Adaptimmune, Amgen, Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, MedImmune, Mirati, MiRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda Travel, Accommodations, Expenses: LOXO, MiRNA; Consulting or advisory role: Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer (Ad Board and Speakers Bureau), Genentech, GLG, Group H, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, Trieza Therapeutics other ownership interests: Molecular Match (Advisor), OncoResponse (founder), Presagia Inc (Advisor). Y.-K.K. consulting or advisory role: Lilly\/ImClone; Novartis; Ono Pharmaceutical; Roche\/ Genentech; Taiho Pharmaceutical; research funding: Bayer; Novartis; Roche\/Genentech. J.Sa. Honoraria: Celgene; consulting or Advisory Role: Celgene. A.B. Honoraria: Vascular Biogenics; Consulting or Advisory Role: NanoTX; Teleflex Medical Research Funding: Mirna Therapeutics (Inst); Threshold Pharmaceuticals; Patents, Royalties, other intellectual property: NanoTx Pharmaceuticals; travel, accommodations, expenses: Vascular Biogenics. G.F. Royalties: Wolters Kluwer; Advisory role: EMD Serono; Travel: Bristol-Myers Squibb, EMD Serono, Millennium; Research funding: 3-V Biosciences, Abbvie, Aileron, American Society of Clinical Oncology, Amgen, ARMO, AstraZeneca, BeiGene, Biothera, Celldex, Celgene, Ciclomed, Curegenix, Curis, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Fujifilm, Genmab, GlaxoSmithKline, Hutchison MediPharma, Ignyta, Incyte, Jacobio, Jounce, Kolltan, Loxo, MedImmune, Millennium, Merck, miRNA Therapeutics, National Institutes of Health, Novartis, OncoMed, Oncothyreon, Precision Oncology, Regeneron, Rgenix, Strategia, Syndax, Taiho, Takeda, Tarveda, Tesaro, Tocagen, U.T. MD Anderson Cancer Center, Vegenics. A.G.B. employment: Mirna Therapeutics; stock and other ownership interests: Mirna Therapeutics Patents, royalties, other intellectual property: inventor on patents and patent applications assigned to Mirna Therapeutics. J.St. employment: Mirna Therapeutics; stock and other ownership interests: Mirna Therapeutics. S.S. employment: Mirna Therapeutics; stock and other ownership interests: Mirna Therapeutics. S.K. employment: Mirna Therapeutics; Leadership: Mirna Therapeutics; stock and other ownership interests: Mirna Therapeutics; Pfizer; Patents, Royalties, other intellectual property: listed as an inventor on patent applications, but no ownership interest or royalties. M.S.B. consulting or advisory role: Bayer; Celgene; Ipsen; Research funding: Celgene; Mirna Therapeutics; Precision Biologics; Travel, Accommodations, Expenses: Mirna Therapeutics; Precision Biologics. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Funded by Mirna Therapeutics, Inc.; The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}